Agent for treatment of disorders of the cerebro-neural transmiss

Details Agent for treatment of disorders of the cerebro-neural transmiss Agent for treatment of disorders of the cerebro-neural transmiss

1991-10-23

1992-10-06

Tsang, Cecilia

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

544377, 544398, 544403, A61K 31495, C07D29500

Patent

active

051531984

ABSTRACT:
A compound of the formula [II] or pharmaceutically acceptable salt thereof, ##STR1## wherein R.sup.1 is hydrogen or fluorine;

REFERENCES:
patent: 3957788 (1976-05-01), Nishimura et al.
patent: 4265894 (1981-05-01), Gootjes et al.
patent: 4656175 (1987-04-01), Bjork et al.
patent: 4757074 (1988-07-01), Coker et al.
Nishimura et al., Chemical Abstract, 109579j, vol. 89, (1978), p. 932.
Iwao et al., Chemical Abstract, 149568t, vol. 109, (1988), p. 742.
R. P. Shank et al., "Preclinical Evaluation of McN-5707 as a Potential Antidepressant", J. Pharm. Exp. Ther., vol. 242, No. 1, pp. 74-84.
C. Idzikowski et al., "5-Hydroxytryptamine-2 Antagonist Increases Human Slow Wave Sleep", Brain Research, 378, (1986), pp. 164-168.
Irwin Lucki et al., "Differential Actions of Serotonin Antagonists on Two Behaviorial Models of Serotonin Receptor Activation in the Rat", J. Pharm. Exp. Ther., vol. 228, (1984), pp. 133-139.

Affiliated with

Also associated with

Rating

Agent for treatment of disorders of the cerebro-neural transmiss does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Agent for treatment of disorders of the cerebro-neural transmiss, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Agent for treatment of disorders of the cerebro-neural transmiss will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1189308